On September 9, 2026 Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, reported that it has entered into a research collaboration and license agreement with RayzeBio, Inc., a clinical-stage radiopharmaceutical company with a mission to transform the lives of people with cancer, to advance a novel radiopharmaceutical program focused on two undisclosed targets.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Ratio will receive an upfront payment and is eligible to receive development, regulatory and commercial milestone payments, as well as royalties on net sales. The companies will apply their respective discovery, translational and radiopharmaceutical expertise to design, evaluate and optimize a next-generation clinical development candidate. RayzeBio has an exclusive worldwide license to candidates and products developed under the program and, following completion of specified research, translational and candidate-assessment activities led by Ratio, will assume responsibility for further development, manufacturing and commercialization worldwide. "The team at Ratio is proud to partner with RayzeBio to advance a next-generation novel radiopharmaceutical approach," said Jack Hoppin, Ph.D., Chief Executive Officer of Ratio. "By bringing together the complementary scientific expertise, technologies, and capabilities of both organizations, we believe this collaboration creates an opportunity to develop a differentiated therapeutic candidate. Together, Ratio’s discovery and translational capabilities and RayzeBio’s complementary radiopharmaceutical expertise position us to explore innovative approaches aimed at improving tumor targeting, retention, and therapeutic efficacy, with the goal of delivering meaningful benefits for patients with cancer."
"The collaboration with Ratio represents an exciting opportunity to explore the potential of novel radiopharmaceutical approaches designed to address the complexity and heterogeneity of cancer," said Ben Hickey, President of RayzeBio. "The combination of our respective technologies and complementary development expertise creates a strong foundation for generating a novel differentiated therapeutic candidate. We believe this approach has the potential to support more precise tumor targeting and expand future therapeutic options for patients with cancer."
(Press release, Ratio Therapeutics, SEP 9, 2026, View Source [SID1234670674])